DNAPrint Genomics

DNAPrint Genomics FCF/Debt

The Free Cash Flow to Debt Ratio of DNAPrint Genomics (DNAG) as of Sep 27, 2026 is -82.46 %.

FCF/Debt

-82.46 %

Last updated:

Free Cash Flow to Debt Ratio of DNAPrint Genomics is 2026 -82.46 % . Free Cash Flow to Debt Ratio of DNAPrint Genomics was 2025 - . It decreases by % lower compared to the previous year.

The DNAPrint Genomics FCF/Debt history

The DNAPrint Genomics FCF/Debt history
YEARFCF/DebtYoY
-82.46 %—
Access this data via the Eulerpool API

DNAPrint Genomics Stock analysis

What does DNAPrint Genomics do? DNAPrint Genomics Inc. was an American company specializing in researching genetic differences and their impact on health, diagnostics, and forensic applications. Founded in Sarasota, Florida in 1997, originally named Genaissance Pharmaceuticals, the company focused on medical research. In 2005, it changed its name to DNAPrint Genomics and shifted its focus to genetic testing development. The company's business model included developing and marketing molecular tests that can reveal an individual's genetic background, providing access to new markets and customers. DNAPrint Genomics offered various product lines for disease diagnosis, including tests for identifying and diagnosing specific diseases like breast cancer, colon cancer, and Alzheimer's. They also provided diagnostics for personalized medicine, matching medication to individuals' genetic predispositions. However, the company gained attention primarily for its forensic applications. They developed a system called DNAWitness, allowing comparison of unknown DNA samples with DNA databases to create offender profiles. The system was used by law enforcement agencies in the U.S. to aid crime investigation and was also involved in international police collaborations. DNAPrint Genomics pursued patents and partnerships with other companies to expand access to new technologies and developments, aiming to position itself in the international market. In 2008, the company announced its discontinuation due to economic reasons, facing complications in selling its DNAWitness system and encountering difficulties in selling its diagnostic tests. Despite having promising products, the company was unable to stabilize its market position and become profitable. DNAPrint Genomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DNAPrint Genomics stock

Free Cash Flow to Debt Ratio of DNAPrint Genomics is -82.46 % in 2026.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio DNAPrint Genomics since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's DNAPrint Genomics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — DNAPrint Genomics

All Key Metrics — DNAPrint Genomics